Hepatobiliary Neoplasm clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
“Volunteer for the DASH Trial and contribute to discoveries that may improve health care for you, your family, and your community!”
open to eligible people ages 18 years and up
The dose escalation phase of this trial identifies the safety, side effects and best dose of ceralasertib (AZD6738) when given in combination with trastuzumab deruxtecan (DS-8201a) in treating patients with solid tumors that have a change (mutation) …
at UC Davis UC Irvine
Our lead scientists for Hepatobiliary Neoplasm research studies include Jonathan W. Riess Farshid Dayyani.
Last updated: